286 related articles for article (PubMed ID: 24393821)
1. [Role of individualized dosing in oncology: are we there yet?].
Joerger M
Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
[TBL] [Abstract][Full Text] [Related]
2. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Zaibet S; Vauchier C; Khoudour N; Roulleaux Dugage M; Korb-Savoldelli V; Alexandre J; Blanchet B; Goldwasser F; Thomas-Schoemann A; Bellesoeur A
Bull Cancer; 2018 Nov; 105(11):1102-1109. PubMed ID: 30309623
[TBL] [Abstract][Full Text] [Related]
3. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N
Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature.
Fahmy A; Hopkins AM; Sorich MJ; Rowland A
Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):803-821. PubMed ID: 34278936
[No Abstract] [Full Text] [Related]
5. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic issues on cancer pharmacotherapy].
Tanigawara Y
Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
Lucas CJ; Martin JH
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
10. Dose calculation of anticancer drugs.
Gao B; Klumpen HJ; Gurney H
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1307-19. PubMed ID: 18798700
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
12. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
[TBL] [Abstract][Full Text] [Related]
13. [Determination of blood levels for oral anticancer drugs].
van Erp NP; van der Graaf WT
Ned Tijdschr Geneeskd; 2014; 158():A7884. PubMed ID: 25467023
[TBL] [Abstract][Full Text] [Related]
14. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
15. The past, present, and future of chemotherapy with a focus on individualization of drug dosing.
DeRidder L; Rubinson DA; Langer R; Traverso G
J Control Release; 2022 Dec; 352():840-860. PubMed ID: 36334860
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
17. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
Levêque D; Becker G
Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
[No Abstract] [Full Text] [Related]
18. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations.
Ferrer F; Fanciullino R; Milano G; Ciccolini J
Clin Pharmacol Ther; 2020 Sep; 108(3):458-470. PubMed ID: 32557660
[TBL] [Abstract][Full Text] [Related]
19. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
20. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
Erku D; Schneider J; Scuffham P
Pharmacol Res Perspect; 2021 Oct; 9(5):e00862. PubMed ID: 34546005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
